Back to Search
Start Over
New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2.
- Source :
-
Journal of Neuroimmunology . Oct2016, Vol. 299, p107-111. 5p. - Publication Year :
- 2016
-
Abstract
- Low-dose interleukin-2 (IL-2) restores the balance of regulatory and effector T cells. We aimed to determine the feasibility of low-dose IL-2 as a treatment for refractory autoimmune encephalitis (AE). Ten patients who had received low-dose IL-2 were retrospectively identified. We observed an improvement in the modified Rankin Scale scores of six patients at the last follow-up compared with the scores at the initiation of low-dose IL-2 ( p = 0.014). One patient experienced treatment-related grade 3 neutropenia. Overall, low-dose IL-2 is a feasible and relatively safe treatment for AE patients who are refractory to the first- and second-line immunotherapies. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01655728
- Volume :
- 299
- Database :
- Academic Search Index
- Journal :
- Journal of Neuroimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 118696363
- Full Text :
- https://doi.org/10.1016/j.jneuroim.2016.09.001